HS-20117

DRUG4 trials

Sponsors

Hansoh BioMedical R&D Company, Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorsColorectal CancerLung CancerNon-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung CancerSolid Tumor

Phase 1

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Not yet recruitingNCT05940116

Hansoh BioMedical R&D CompanyNon-Small Cell Lung Cancer, Solid Tumor

Start: 2023-07-20End: 2027-07-30Target: 322Updated: 2023-07-12

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Not yet recruitingNCT06963502

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer

Start: 2025-05-30End: 2030-04-30Target: 762Updated: 2025-05-09

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not yet recruitingNCT07414953

Jiangsu Hansoh Pharmaceutical Co., Ltd.Lung Cancer

Start: 2026-03-30End: 2028-11-30Target: 400Updated: 2026-02-17

Phase 2

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

RecruitingNCT06417008

Hansoh BioMedical R&D CompanyNon-Squamous Non-Small Cell Lung Cancer

Start: 2024-05-28End: 2030-06-01Target: 1080Updated: 2025-08-01